Patent Foramen Ovale (PFO) and Risk of Perioperative Stroke
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether having a condition called Patent Foramen Ovale (PFO)—a small hole in the heart that usually doesn’t cause symptoms—can increase the risk of having a stroke during or after non-heart-related surgeries. Researchers want to find out if patients with this condition are more likely to experience strokes, both obvious and subtle, when they undergo surgeries like orthopedic or gynecologic procedures.
To participate, you need to be at least 18 years old and scheduled for an elective surgery that doesn’t involve the heart or blood vessels. You should also expect to stay in the hospital for at least two days after your surgery. However, people who require long-term blood-thinning medications, have certain health issues that could raise stroke risks, or cannot have an MRI will not be eligible for the study. If you join, the study will help researchers understand better the risks associated with PFO, which could improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. patients 18 years and above;
- • 2. referred for an elective, non-cardiac, non-vascular and non-brain surgery;
- • 3. with an estimated hospital length of stay ≥2 days. We will include patients referred for general, orthopedic, urological, gynecologic, spinal or thoracic surgery.
- Exclusion Criteria:
- • 1. patients in need for long-term, perioperative anticoagulants;
- • 2. those with comorbidities that potentially increase the risk of perioperative stroke;
- • 3. contraindications to MRI;
- • 4. unable to complete or adhere to the study.
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Eric Horlick, MD
Principal Investigator
University Health Network, Peter Munk Cardiac Centre
Lusine Abrahamyan, MD, PhD
Principal Investigator
University Health Network, Theta Collaborative
Aleksandra Pikula, MD
Principal Investigator
University Heath Network, Division of Neurology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials